Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Jul 28;5(1):1197.
doi: 10.1186/s40064-016-2660-0. eCollection 2016.

Management of relapsed ovarian cancer: a review

Gonzalo H Giornelli  1
Affiliations
Review

Management of relapsed ovarian cancer: a review

Gonzalo H Giornelli. Springerplus. .

Abstract

Around 70 % of ovarian cancer patients relapse after primary cytoreductive surgery and standard first-line chemotherapy. The biology of relapse remains unclear, but cancer stem cells seem to play an important role. There are still some areas of controversy on how to manage these relapses and or progressions that occur almost unavoidably in the course of this disease with shorter intervals between them as the natural history of this disease develops. The goal of treatments investigated in this neoplasm has shifted to maintenance therapy, trying to extend the progression free intervals in a disease that is becoming more and more protracted.

Keywords: Chemotherapy; Cytoreductive surgery; Ovarian cancer; Relapse.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Natural history of ovarian cancer evolution
Fig. 2
Fig. 2
“Study 19”, progression free survival according to BRCA status. Adapted from Matulonis et al. (2016), Ledermann et al. (2014), Birrer et al. (2015)
Fig. 3
Fig. 3
Ceridanib + olaparib versus olaparib in platinum sensitive relapse (PFS according to BRCA status). Adapted from Liu et al. (2014a)
See this image and copyright information in PMC

References

    1. Aghajanian C, Goff B, Nycum LR. Final overall survival and safety analysis of OCEANS, a phase 3 trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent ovarian cancer. Gynecol Oncol. 2015;139(1):10–16. doi: 10.1016/j.ygyno.2015.08.004. - DOI - PMC - PubMed
    1. AGO Study Group (2015) Study comparing tumor debulking surgery versus chemotherapy alone in recurrent platinum-sensitive ovarian cancer (DESKTOP III). ClinicalTrials.gov Identifier: NCT01166737. https://clinicaltrials.gov/ct2/show/NCT01166737?term=NCT01166737&rank=1. Accessed Jan 2016
    1. Alsop K, Fereday S, Meldrum C. CA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group. J Clin Oncol. 2012;30(21):2654–2663. doi: 10.1200/JCO.2011.39.8545. - DOI - PMC - PubMed
    1. Armstrong DK, Bundy B, Wenzel L. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med. 2006;354(1):34–43. doi: 10.1056/NEJMoa052985. - DOI - PubMed
    1. Audeh MW, Carmichael J, Penson RT. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet. 2010;376(9737):245–251. doi: 10.1016/S0140-6736(10)60893-8. - DOI - PubMed